

Human Growth Hormone Receptor, isoform 1 Reporter Assay System (GHR)

3x 32 Assays in 96-well Format Product # IB14001-32

Technical Manual

(version 7.2b)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service: 814-234-1919; FAX 814-272-0152 customerserv@indigobiosciences.com

Technical Service: 814-234-1919 techserv@indigobiosciences.com



Human GHR Reporter Assay System 3x 32 Assays in 96-well Format

I. Description
The Assay System
The Assay Chemistry
Preparation of Test Compounds
Assay Scheme5
• Assay Performance
II. Product Components & Storage Conditions6
III. Materials to be Supplied by the User6
IV. Assay Protocol
■ A word about Inhibtion-mode assay setup7
■ DAY 1 Assay Protocol7
■ DAY 2 Assay Protocol9
V. Related Products
VI. Limited Use Disclosures
APPENDIX 1: Example Scheme for Serial Dilutions11

I. Description

The Assay System

This assay utilizes proprietary human cells that provide constitutive expression of the **Human Growth Hormone Receptor**, *isoform 1* (GHR).

GHR is a single-pass transmembrane receptor that functions as a homo-dimer. Growth Hormone (GH, *aka* Somatotropin) activates GHR to initiate signal transduction by a variety of pathways, including Ras/ERK, PI3K/Akt, and JAK2/STAT1,3,5,6.¹ The activation of these various pathways may culminate in the activation of cytosolic targets, or in the activation of specific transcription factors and the induction of their respective target genes.

JAK2 dependent phosphorylation and activation of the transcription factor STAT5 is a prominent outcome of GHR activation, and it is the signaling pathway exploited by the reporter cells included in this assay kit. Specifically, INDIGO's Reporter Cells contain the luciferase reporter gene functionally linked to an engineered minimal promoter sequence with upstream tandem STAT5 genetic response element (GRE) sequences. Growth hormone activates the GHR in a dose-dependent manner, thereby triggering the JAK2/STAT signal transduction cascade. Activated STAT5 binds to its consensus GRE's to initiate the formation of a complete transcription complex that drives expression of the Luc reporter gene. Therefore, quantifying changes in luciferase activity from peptide-, drug- or antibody-treated reporter cells relative to that of 'untreated' cells provides a sensitive, dose-dependent surrogate measure of changes in the activity of GHR.

GH / GHR play critical roles in the physiological processes of early bone and muscle development, and the regulation of lipid and carbohydrate metabolism. Also important is the role of GH-dependent activation of GHR in modulating the production and secretion of insulin-like growth factor-1 (IGF-1) within the liver, known as the GH-IGF1 axis. Dysregulation of GH production, either up or down, has significant physiological consequences. The development of body mass and size, insulin sensitivity, oncogenesis, and the onset of obesity, liver disease and age-related diseases are greatly impacted by a chronic imbalance of GH production and/or function.

Not surprisingly, the development of novel GH-like peptide therapeutics, as well as small molecule and antibody modulators of GHR activity, continues to command much interest.² Accordingly, the primary application of this reporter assay is to screen test materials for any functional activity, either agonistic or inhibitory, that they may exert against the human GHR.

INDIGO's Reporter Cells are transiently transfected and prepared as frozen stocks using a proprietary **CryoMite**TM process. This cryo-preservation method allows for the immediate dispensing of healthy, division-competent reporter cells into assay plates. There is no need for intermediate treatment steps such as spin-and-rinse of cells, viability determinations or cell titer adjustments prior to assay setup.

INDIGO's assay kits provide the convenience of an all-inclusive cell-based assay system. In addition to GHR Reporter Cells, provided are two optimized media for use in recovering the cryopreserved cells and for diluting test samples, the physiological activator human growth hormone (GH), Luciferase Detection Reagents, and a cell culture-ready assay plate.

¹ Dehkhoda, F, *et al.* (2018) The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Frontiers in Endocrinology 9:35, 1-23.

² Lu,M, *et al.* (2019) Targeting growth hormone function: strategies and therapeutic applications. Signal Transduction and Targeted Therapy (Springer Nature) 4:3, 1-11.

The Assay Chemistry

INDIGO's receptor assay kits capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg⁺²-dependent reaction that consumes O₂ and ATP as co-substrates to yield oxyluciferin, AMP, PP_i, CO₂, and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

Assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

Preparation of Test Compounds

Small molecule compounds are typically solvated in DMSO at high concentrations; ideally 1,000x-concentrated stocks relative to the highest desired treatment concentration in the assay. Using high-concentration stocks minimizes DMSO carry-over into the assay plates. Note that the final concentration of DMSO carried over into assay wells should *never* exceed 0.4%.

For protein or antibody samples it is recommended to solvate the materials in aqueous buffered solutions supplemented with carrier protein (e.g., PBS + 0.1% BSA) at concentrations no less than 10x relative to the highest desired treatment concentration. The GH stock included with this kit is prepared in PBS + 0.1% BSA at a 100x-concentration relative to the highest recommended treatment (refer to APPENDIX 1).


Immediately prior to setting up an assay the prepared stocks are serially diluted using **Compound Screening Medium (CSM)** to achieve the desired assay concentrations, as described in *Step 7*.

NOTE: CSM is formulated to help stabilize hydrophobic small molecule test compounds in the aqueous environment of the treatment media. Nonetheless, high concentrations of small organic molecules diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that compound dilutions are prepared in CSM immediately prior to assay setup and are then treated as 'single-use' reagents.

Assay Scheme

Figure 1. Assay workflow.

In brief, $200~\mu l$ of Reporter Cells is dispensed into wells of the assay plate and for 4-6 hours. Following the pre-incubation period, culture media are discarded and $200~\mu l/well$ of the prepared treatment media are added. Following 22-24 hr incubation, discard the treatment media and add Luciferase Detection Reagent. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



Assay Performance

Human Growth Hormone Receptor Assay




Figure 2. GHR Activation assay. Dose-response analyses were performed according to the protocol provided in this Technical Manual. $200 \,\mu\text{l}$ / well of GHR Reporter Cell suspension was dispensed into the 96-well assay plate, which was then incubated for 4 hours. The concentrated stock of the peptide GH (provided) was further diluted using CSM to produce treatment media at the desired assay concentrations. The pre-culture media were discarded from the assay wells and $200 \,\mu\text{l}$ per well of the prepared treatment media were dispensed (n = 3/conc.), including 'untreated' control wells. 'Mock' reporter cells, which contain the STAT5-Luc reporter gene, but lack expression of GHR, were similarly treated with GH. Following a 22 hr incubation period treatment media were discarded, Luciferase Detection Reagent was added, and luminescence intensity per well was quantified. Values of average relative light units (RLU) and corresponding values of standard deviation (SD), percent coefficient of variation (%CV), Fold-Activation and Z' were determined for each treatment concentration. Non-linear regression analyses of Fold Activation vs. Log₁₀[ng/mL] and EC₅₀ determination was performed using GraphPad Prism software.

$$Z' = 1 - [3*(SD^{Reference} + SD^{Untreated}) / (RLU^{Reference} - RLU^{Untreated})]$$

³ Zhang JH, *et al.* (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen.:**4**(2), 67-73.

II. Product Components & Storage Conditions

This Human GHR Assay kit contains materials to perform three distinct groups of assays in the format of a 96-well plate. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

Cryopreserved mammalian cells are temperature sensitive! To ensure maximal viability the tube of Reporter Cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in Step 2 of this protocol.

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inspect and inventory the individual kit components please be sure to first transfer and submerge the tube of reporter cells in dry ice.

The aliquot of Reporter Cells is provided as a single-use reagent. Once thawed, reporter cells can NOT be refrozen, nor can they be maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

Kit Components	Amount	Storage Temp.
• GHR Reporter Cells	3 x 0.6 mL	-80°C
• Cell Recovery Medium (CRM)	2 x 10.5 mL	-20°C
• Compound Screening Medium (CSM)	1 x 45 mL	-20°C
• GH, 30 μg/ml (in PBS/0.1%BSA) (physiological activator of GHR)	1 x 100 μL	-20°C
Detection Substrate	3 x 2.0 mL	-80°C
• Detection Buffer	3 x 2.0 mL	-20°C
• Plate Frame	1	ambient
 Snap-in 8-well strips (white, sterile, collagen-coated wells) 	12	-20°C

NOTE: This Assay kit contains one 96-well assay plate in which the assay wells have been collagen-coated and dried; the assay plate should be <u>stored frozen</u> (-20°C or colder) until use.

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

DAY 1

- container of dry ice (see Step 2)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), *or* deep-well plates, *or* appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).
- Optional: clear 96-well assay plate, cell culture treated, for viewing cells on Day 2.

DAY 2 plate-reading luminometer.

IV. Assay Protocol

The assay protocol begins on the next page. Please review the entire protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on *Day 1*, requiring less than 2 hours of bench work and a 4 hr incubation step to complete. *Steps 12-17* are performed on *Day 2* and require less than 1 hour to complete.

A word about Inhibition-mode assay setups

Receptor inhibition assays expose the Reporter Cells to a fixed, sub-maximal concentration (typically between $EC_{50}-EC_{85}$) of a known agonist AND varying concentrations of the test compound(s) to be evaluated for chemical inhibition. This GHR Assay kit includes a 30 µg/mL stock solution of human Growth Hormone (GH), the physiological agonist of GHR, that may be used to set up inhibition-mode assays. 60 ng/mL GH approximates EC_{80} in this assay. Hence, it presents a suitable concentration of agonist to use when screening test materials for inhibitory activities.

Add GH to a bulk volume of **CSM**, as described above. This agonist-supplemented medium is then used to prepare serial dilutions of test material stocks to achieve the desired respective final assay concentrations. This is an efficient and precise method of setting up GHR inhibition assays, and it is the method presented in *Step 7b* of this protocol.

DAY 1 Assay Protocol: All steps should be performed using aseptic technique.

- **1.**) Remove the **2 tubes** of **Cell Recovery Medium (CRM)** from freezer storage, thaw and equilibrate to 37°C using a water bath.
- **2.) Rapid Thaw of the Reporter Cells:** *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

Second, retrieve **Reporter Cells** from -80°C storage and place them directly into <u>dry ice</u> to transport them to the laminar flow hood: 1 tube for 32 assay wells, 2 tubes for 64 assay wells, or 3 tubes for 96 assay wells. When ready to begin, transfer the tube(s) of reporter cells into a rack and, without delay, perform a rapid thaw of the frozen cells by transferring **6.4 ml** of pre-warmed CRM into each tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be **7.0 ml** per tube.

Third, during the 5 - 10 minutes incubation period, work in the cell culture hood to *carefully* mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.

- **3.)** Retrieve the tube(s) of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.
- **4.**) If more than one tube of Reporter cells was thawed, combine them and gently invert several times to disperse cell aggregates and gain a homogenous cell suspension. Dispense **200** μ l / well of cell suspension into the assay plate.
 - *NOTE 4.1:* If INDIGO's Live Cell Multiplex Assay is to be incorporated, a minimum of 3 'blank' wells (meaning cell-free, but containing 'CSM') must be included in the assay plate to allow quantification of fluorescence background (refer to the LCMA Technical Manual).
 - NOTE 4.2: Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling in the reservoir during the dispensing period. Likewise, take care to ensure precision in dispensing exact volumes across the assay plate.
 - *NOTE 4.3:* Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear, collagen-coated 96-well assay plate. Continue to process the assay plate in identical manner to the white assay plate.

- 5.) Pre-incubate reporter cells: Place the assay plate into a cell culture incubator (37°C, ≥ 70% humidity, 5% CO₂) for 4 6 hours.
- **6.) Near the end of the pre-culture period:** Remove Compound Screening Medium **(CSM)** from freezer storage and thaw in a 37°C water bath.
- 7.) Prepare the Test Compound(s) and Reference Compound treatment media: Use CSM to prepare an appropriate dilution series of the reference and test compound stocks. Prepare all treatment media at the desired final assay concentrations. In *Step 9*, the prepared treatment media will be dispensed at 200 μ l / well into the strip wells. Manage dilution volumes carefully; this assay kit provides **45 ml** of CSM.

NOTE: Total DMSO carried over into assay reactions should never exceed 0.4%.

a. Agonist-mode assays. This GHR Assay kit includes a concentrated stock of GH, 30 μg/ml prepared in PBS/0.1%BSA. The following 7-point treatment series, with concentrations generated using serial 3-fold dilutions, provides a complete dose-response: 300, 100, 33.3, 11.1, 3.70, 1.23, and 0.412 ng/ml. **APPENDIX 1** provides guidance for generating such a dilution series. Always include 'no treatment' control wells.

~ or ~

- **b.** Inhibition-mode assays. When setting up inhibition assays, first supplement a bulk volume of CSM with the challenge agonist GH to achieve an EC₅₀ EC₈₀ concentration (refer to "A word about inhibition-mode assay setup", pg. 7). The GH-supplemented CSM is then used to generate dilutions of test compound stocks to achieve the desired series of treatment concentrations.
- **8.)** At the end of the cell pre-culture period: Discard the culture media. Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using an 8-pin manifold (e.g., Wheaton Science Microtest Syringe Manifold, #851381) affixed to a vacuum-trap apparatus. Do *not* touch the well bottom or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the cells and greatly increased well-to-well variability.
- 9.) Dispense 200 μ l of each treatment media into appropriate wells of the assay plate.
- **10.**) Transfer the assay plate into a cell culture incubator for <u>22 24 hours</u>.

 NOTE: Ensure a high-humidity (≥ 70%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.
- 11.) For greater convenience on *Day* 2, retrieve the appropriate number of vials of **Detection Substrate** *and* **Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

- **DAY 2 Assay Protocol:** Subsequent manipulations do *not* require special regard for aseptic technique and may be performed on a bench top.
- **12.**) Approximately 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature.
 - *NOTE:* Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.
- 13.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single $\underline{5}$ second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.
- **14.**) *Immediately before proceeding to Step 15*: To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml_volume of Luciferase Detection Reagent (LDR). Mix gently to avoid foaming.
- **15.**) Following 22 24 hours incubation in treatment media, remove media contents from each well of the assay plate (as before in *Step 8*).
- **16.)** Add $\underline{100 \, \mu l}$ of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least $\underline{5 \, \text{minutes}}$ following the addition of LDR. Do not shake the assay plate during this period.
- 17.) Quantify luminescence.

V. Related Products

Product No.	Product Descriptions	
Human Growth Hormone Receptor Assay Products		
IB14001-32	GHR Reporter Assay System 3x 32 assays in 8-well strips (96-well plate format)	
IB14001	GHR Reporter Assay System 1x 96-well format assay	
IB14002	GHR Reporter Assay System 1x 384-well format assays	
Bulk volumes of GHR Assay Reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire.		

LIVE Cell Multiplex (LCM) Assay		
LCM-01	Reagent volumes sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats	
LCM-05	Reagent in 5x bulk volume to perform 480 Live Cell Assays contained in 5 x 96-well assay plates	
LCM-10	Reagent in 10x bulk volume to perform 960 Live Cell Assays contained in 10 x 96-well assay plates	

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products offered by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

"CryoMite" is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA).

Product prices, availability, specifications, claims and technical protocols are subject to change without prior notice. The printed Technical Manual provided in the kit box will always be the most current version available.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All rights reserved.

APPENDIX 1

Example scheme for the serial dilution of Human GH and the setup of a GHR dose-response assay.

